How to buy BioCardia stock | $2.65

BioCardia, Inc is a biotechnology business based in the US. BioCardia shares (BCDA) are listed on the NASDAQ and all prices are listed in US Dollars. BioCardia employs 20 staff and has a trailing 12-month revenue of around USD$314,000.

How to buy shares in BioCardia

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for BioCardia. Find the stock by name or ticker symbol: BCDA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioCardia reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.65, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioCardia, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of BioCardia. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BioCardia share price

Use our graph to track the performance of BCDA stocks over time.

BioCardia shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$2.65
52-week range	USD$1.91 - USD$6.5
50-day moving average	USD$2.9106
200-day moving average	USD$2.5439
Wall St. target price	USD$12.88
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.2

Buy BioCardia shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy BioCardia stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BioCardia, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioCardia price performance over time

Historical closes compared with the close of $2.65 from 2020-12-09

1 week (2021-01-09)	N/A
1 month (2020-12-18)	-25.56%
3 months (2020-10-16)	15.22%
6 months (2020-07-17)	11.34%

1 year (2020-01-17)	-48.44%
2 years (2019-01-18)	96.30%
3 years (2018-01-18)	3.01
5 years (2016-01-16)	N/A

BioCardia financials

Revenue TTM	USD$314,000
Gross profit TTM	USD$-8,210,000
Return on assets TTM	-96.41%
Return on equity TTM	-333.43%
Profit margin	0%
Book value	$0.331
Market capitalisation	USD$55.4 million

TTM: trailing 12 months

Shorting BioCardia shares

There are currently 12,431 BioCardia shares held short by investors – that's known as BioCardia's "short interest". This figure is 10.4% up from 11,265 last month.

There are a few different ways that this level of interest in shorting BioCardia shares can be evaluated.

BioCardia's "short interest ratio" (SIR)

BioCardia's "short interest ratio" (SIR) is the quantity of BioCardia shares currently shorted divided by the average quantity of BioCardia shares traded daily (recently around inf billion). BioCardia's SIR currently stands at 0. In other words for every 100,000 BioCardia shares traded daily on the market, roughly 0 shares are currently held short.

However BioCardia's short interest can also be evaluated against the total number of BioCardia shares, or, against the total number of tradable BioCardia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCardia's short interest could be expressed as 0% of the outstanding shares (for every 100,000 BioCardia shares in existence, roughly 0 shares are currently held short) or 0.0015% of the tradable shares (for every 100,000 tradable BioCardia shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioCardia.

Find out more about how you can short BioCardia stock.

BioCardia share dividends

We're not expecting BioCardia to pay a dividend over the next 12 months.

Have BioCardia's shares ever split?

BioCardia's shares were split on a 1:9 basis on 6 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioCardia shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for BioCardia shares which in turn could have impacted BioCardia's share price.

BioCardia share price volatility

Over the last 12 months, BioCardia's shares have ranged in value from as little as $1.91 up to $6.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCardia's is 2.0343. This would suggest that BioCardia's shares are significantly more volatile than the average for this exchange and represent a higher risk.

BioCardia overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.

Frequently asked questions

• What percentage of BioCardia is owned by insiders or institutions?

  Currently 45.779% of BioCardia shares are held by insiders and 14.56% by institutions.

• How many people work for BioCardia?

  Latest data suggests 20 work at BioCardia.

• When does the fiscal year end for BioCardia?

  BioCardia's fiscal year ends in December.

• Where is BioCardia based?

  BioCardia's address is: 125 Shoreway Road, San Carlos, CA, United States, 94070

• What is BioCardia's ISIN number?

  BioCardia's international securities identification number is: US09060U5074

• What is BioCardia's CUSIP number?

  BioCardia's Committee on Uniform Securities Identification Procedures number is: 09060U101